Abstract
Dissolving microneedle (DMN) arrays are minimally invasive
devises that consist of a series of microscopic needles on a base
support. Upon insertion into the skin, the needles dissolve depositing
their payload (Figure 1(A–C)) [1]. DMN have received substantial
interest for intradermal vaccination due to their ease of use
and possibility for self-administration. DMN research is close to
commercialization. However, moving forward, there remain a
number of concerns which warrant investigation. Herein, such
considerations are discussed with a specific focus on the key
challenges for DMN industrialization being highlighted.
devises that consist of a series of microscopic needles on a base
support. Upon insertion into the skin, the needles dissolve depositing
their payload (Figure 1(A–C)) [1]. DMN have received substantial
interest for intradermal vaccination due to their ease of use
and possibility for self-administration. DMN research is close to
commercialization. However, moving forward, there remain a
number of concerns which warrant investigation. Herein, such
considerations are discussed with a specific focus on the key
challenges for DMN industrialization being highlighted.
Original language | English |
---|---|
Pages (from-to) | 1039-1043 |
Number of pages | 4 |
Journal | Expert Opinion on Drug Delivery |
Volume | 15 |
Issue number | 11 |
Early online date | 11 Sept 2018 |
DOIs | |
Publication status | Published online - 11 Sept 2018 |
Keywords
- Dissolving
- microneedle
- vaccination
- immunization
- scale-up